Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2018-07-04 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2017年年度分红派息实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2017 annual dividend distribution plan approved at the 2017 Annual General Meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend distribution. It references the shareholder meeting resolutions and the dividend payment schedule. The document does not contain full financial statements or comprehensive financial performance data, nor is it a report or presentation. It is specifically about the dividend payment details following shareholder approval, which fits the category of Notice of Dividend Amount (DIV). The document length is short (1798 characters), consistent with a dividend announcement rather than a full report.
2018-07-04 Chinese
2017年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2017 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on various proposals including the 2017 annual reports, financial statements, profit distribution, appointment of auditors, and amendments to the company articles. It also includes legal opinions confirming the validity of the meeting and voting process. The content is focused on the official announcement of the AGM resolutions and voting outcomes rather than the full AGM materials or presentations. The document length is about 5099 characters, which is consistent with a detailed announcement rather than a full report or presentation. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-05-25 Chinese
公司章程（2018年5月）
Governance Information Classification · 95% confidence The document is a detailed corporate charter or articles of association for Jinling Pharmaceutical Company Limited. It includes comprehensive provisions on company organization, shareholder rights, board of directors, shareholder meetings, voting procedures, and corporate governance. It references Chinese company law and securities regulations, and outlines the company's structure and rules for operation. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a meeting presentation or transcript, nor a voting result announcement. The document is a governance document detailing internal rules and governance practices of the company. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback.
2018-05-25 Chinese
2017年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2017 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It details the procedures, attendance, voting results, and legality of the AGM. The content focuses on the AGM process and voting outcomes rather than presenting the actual annual report or financial statements. The document is not the annual report itself but a legal opinion related to the AGM. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM.
2018-05-25 Chinese
2018年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 First Quarter Report" of Jinling Pharmaceutical Co., Ltd. It contains detailed financial data for the first quarter of 2018, including revenue, net profit, cash flow, shareholder information, and notes on significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an interim or quarterly financial report. The document length is substantial (over 10,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-26 Chinese
关于召开2017年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, and instructions for shareholders to participate either in person or via internet voting. The document also contains an authorization proxy form for shareholders to delegate voting rights. There is no actual financial data or report content included, only the announcement and procedural details for the AGM. Therefore, this document is not the Annual Report (10-K) or any financial report itself, but rather the official notice and materials related to the AGM meeting. This fits the definition of AGM Information (AGM-R). The document length is about 4970 characters, which is consistent with a detailed AGM notice rather than a full report.
2018-04-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.